dm+d
Unassigned
New Medicines
Pulmonary hypertension when added to background therapy
Information
New molecular entity
Arena
Arena
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Prostacyclin receptor agonist
The estimated annual incidence of PAH in the UK general population ranges from 0.9 to 7.6 cases per 1,000,000 people and the estimated prevalence of PAH in the UK general population is between 6.6 and 26 per 1,000,000 people. These figures are thought to be underestimates due to misdiagnosis or underdiagnoses of PAH patients [1].
Pulmonary hypertension when added to background therapy
Oral